Impact of dorzolamide, benzalkonium-preserved dorzolamide and benzalkonium-preserved brinzolamide on selected biomarkers of oxidative stress in the tear film

Abstract Background Long-term use of topical, especially benzalkonium chloride (BAC)-preserved, antiglaucoma medications can cause a negative impact on the ocular surface. The aim of the study was to assess the effect of topical carbonic anhydrase inhibitors (CAIs) on selected oxidative stress bioma...

Full description

Bibliographic Details
Main Authors: Lech Sedlak, Marta Świerczyńska, Weronika Borymska, Maria Zych, Dorota Wyględowska-Promieńska
Format: Article
Language:English
Published: BMC 2021-09-01
Series:BMC Ophthalmology
Subjects:
Online Access:https://doi.org/10.1186/s12886-021-02079-y
id doaj-2e8f1c01b5144616863c1673200b117b
record_format Article
spelling doaj-2e8f1c01b5144616863c1673200b117b2021-09-05T11:50:55ZengBMCBMC Ophthalmology1471-24152021-09-0121111010.1186/s12886-021-02079-yImpact of dorzolamide, benzalkonium-preserved dorzolamide and benzalkonium-preserved brinzolamide on selected biomarkers of oxidative stress in the tear filmLech Sedlak0Marta Świerczyńska1Weronika Borymska2Maria Zych3Dorota Wyględowska-Promieńska4Department of Ophthalmology, Faculty of Medical Sciences in Katowice, Medical University of Silesia in KatowiceDepartment of Ophthalmology, Faculty of Medical Sciences in Katowice, Medical University of Silesia in KatowiceDepartment of Pharmacognosy and Phytochemistry, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in KatowiceDepartment of Pharmacognosy and Phytochemistry, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in KatowiceDepartment of Ophthalmology, Faculty of Medical Sciences in Katowice, Medical University of Silesia in KatowiceAbstract Background Long-term use of topical, especially benzalkonium chloride (BAC)-preserved, antiglaucoma medications can cause a negative impact on the ocular surface. The aim of the study was to assess the effect of topical carbonic anhydrase inhibitors (CAIs) on selected oxidative stress biomarkers in the tear film. Methods The patients were divided into four sex-matched groups: group C (n = 25) – control group – subjects who did not use topical antiglaucoma medications, group DL (n = 14) – patients using preservative-free dorzolamide, group DL + BAC (n = 16) – patients using topical BAC-preserved dorzolamide, group BL + BAC (n = 17) – patients using BAC-preserved brinzolamide. Subjects in all the study groups have been using the eye drops two times daily for 6–12 months. The oxidative stress biomarkers in the tear film samples were measured: total protein (TP) concentration, advanced oxidation protein products (AOPP) content, total sulfhydryl (-SH) groups content, the activity of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx), as well as Total Oxidant Status (TOS), Total Antioxidant Response (TAR), and Oxidative Stress Index (OSI). Results The advanced oxidation protein products content, Total Oxidant Status as well as superoxide dismutase and catalase activities in the group DL + BAC and BL + BAC were higher in comparison with the group C. The total sulfhydryl groups content was lower in the group DL + BAC and BL + BAC when compared to group C. Oxidative Stress Index was higher in the groups DL + BAC and BL + BAC in comparison with the groups DL and C. Conclusions Use of topical benzalkonium chloride-preserved carbonic anhydrase inhibitors increases oxidative stress in the tear film.https://doi.org/10.1186/s12886-021-02079-yBenzalkonium chlorideDorzolamideBrinzolamideCarbonic anhydrase inhibitorOxidative stressOcular surface
collection DOAJ
language English
format Article
sources DOAJ
author Lech Sedlak
Marta Świerczyńska
Weronika Borymska
Maria Zych
Dorota Wyględowska-Promieńska
spellingShingle Lech Sedlak
Marta Świerczyńska
Weronika Borymska
Maria Zych
Dorota Wyględowska-Promieńska
Impact of dorzolamide, benzalkonium-preserved dorzolamide and benzalkonium-preserved brinzolamide on selected biomarkers of oxidative stress in the tear film
BMC Ophthalmology
Benzalkonium chloride
Dorzolamide
Brinzolamide
Carbonic anhydrase inhibitor
Oxidative stress
Ocular surface
author_facet Lech Sedlak
Marta Świerczyńska
Weronika Borymska
Maria Zych
Dorota Wyględowska-Promieńska
author_sort Lech Sedlak
title Impact of dorzolamide, benzalkonium-preserved dorzolamide and benzalkonium-preserved brinzolamide on selected biomarkers of oxidative stress in the tear film
title_short Impact of dorzolamide, benzalkonium-preserved dorzolamide and benzalkonium-preserved brinzolamide on selected biomarkers of oxidative stress in the tear film
title_full Impact of dorzolamide, benzalkonium-preserved dorzolamide and benzalkonium-preserved brinzolamide on selected biomarkers of oxidative stress in the tear film
title_fullStr Impact of dorzolamide, benzalkonium-preserved dorzolamide and benzalkonium-preserved brinzolamide on selected biomarkers of oxidative stress in the tear film
title_full_unstemmed Impact of dorzolamide, benzalkonium-preserved dorzolamide and benzalkonium-preserved brinzolamide on selected biomarkers of oxidative stress in the tear film
title_sort impact of dorzolamide, benzalkonium-preserved dorzolamide and benzalkonium-preserved brinzolamide on selected biomarkers of oxidative stress in the tear film
publisher BMC
series BMC Ophthalmology
issn 1471-2415
publishDate 2021-09-01
description Abstract Background Long-term use of topical, especially benzalkonium chloride (BAC)-preserved, antiglaucoma medications can cause a negative impact on the ocular surface. The aim of the study was to assess the effect of topical carbonic anhydrase inhibitors (CAIs) on selected oxidative stress biomarkers in the tear film. Methods The patients were divided into four sex-matched groups: group C (n = 25) – control group – subjects who did not use topical antiglaucoma medications, group DL (n = 14) – patients using preservative-free dorzolamide, group DL + BAC (n = 16) – patients using topical BAC-preserved dorzolamide, group BL + BAC (n = 17) – patients using BAC-preserved brinzolamide. Subjects in all the study groups have been using the eye drops two times daily for 6–12 months. The oxidative stress biomarkers in the tear film samples were measured: total protein (TP) concentration, advanced oxidation protein products (AOPP) content, total sulfhydryl (-SH) groups content, the activity of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx), as well as Total Oxidant Status (TOS), Total Antioxidant Response (TAR), and Oxidative Stress Index (OSI). Results The advanced oxidation protein products content, Total Oxidant Status as well as superoxide dismutase and catalase activities in the group DL + BAC and BL + BAC were higher in comparison with the group C. The total sulfhydryl groups content was lower in the group DL + BAC and BL + BAC when compared to group C. Oxidative Stress Index was higher in the groups DL + BAC and BL + BAC in comparison with the groups DL and C. Conclusions Use of topical benzalkonium chloride-preserved carbonic anhydrase inhibitors increases oxidative stress in the tear film.
topic Benzalkonium chloride
Dorzolamide
Brinzolamide
Carbonic anhydrase inhibitor
Oxidative stress
Ocular surface
url https://doi.org/10.1186/s12886-021-02079-y
work_keys_str_mv AT lechsedlak impactofdorzolamidebenzalkoniumpreserveddorzolamideandbenzalkoniumpreservedbrinzolamideonselectedbiomarkersofoxidativestressinthetearfilm
AT martaswierczynska impactofdorzolamidebenzalkoniumpreserveddorzolamideandbenzalkoniumpreservedbrinzolamideonselectedbiomarkersofoxidativestressinthetearfilm
AT weronikaborymska impactofdorzolamidebenzalkoniumpreserveddorzolamideandbenzalkoniumpreservedbrinzolamideonselectedbiomarkersofoxidativestressinthetearfilm
AT mariazych impactofdorzolamidebenzalkoniumpreserveddorzolamideandbenzalkoniumpreservedbrinzolamideonselectedbiomarkersofoxidativestressinthetearfilm
AT dorotawygledowskapromienska impactofdorzolamidebenzalkoniumpreserveddorzolamideandbenzalkoniumpreservedbrinzolamideonselectedbiomarkersofoxidativestressinthetearfilm
_version_ 1717813854885380096